Does Berberine Lower Cholesterol? Strong Evidence, 18 Trials Reviewed

Yes. Across 18 placebo-controlled randomized trials with 1,788 participants, berberine lowered LDL cholesterol by 0.46 mmol/L, about 18 mg/dL, total cholesterol by 0.48 mmol/L and triglycerides by 0.34 mmol/L, with no serious adverse events in any trial (PMID 36941490). It is the quietest strong claim in the berberine literature, and the one with the least hype behind it: on HDAI’s HYPE Index it scores 26, Largely calibrated, with the residual gap coming from surrogate endpoints rather than overclaiming.

Presented By Our Partners

What the trials found

The 2023 meta-analysis is the cleanest estimate because it included only placebo-controlled trials and registered its protocol in advance. Trials ran 4 to 24 weeks, 83 percent were conducted in mainland China or Hong Kong, and gastrointestinal side effects were more common on berberine (2 to 23 percent versus 2 to 15 percent). It also found a sex difference nobody had reported: HDL rose 0.11 mmol/L in women and fell 0.07 mmol/L in men (PMID 36941490). A trial that stopped and restarted berberine in 97 adults with mild hyperlipidemia watched lipids improve on treatment, rebound during a 2-month washout, and improve again on re-treatment, a pattern that strengthens the causal case (PMID 27491226).

How an 18 mg/dL drop compares

Low-intensity statin therapy typically lowers LDL by 20 to 30 percent; for someone starting at 130 mg/dL that is 26 to 39 mg/dL. Berberine’s pooled 18 mg/dL sits below that range. The comparison matters because statins have decades of trials showing fewer heart attacks and strokes, and berberine has none. A lipid number is a surrogate; the outcome is the event it is supposed to predict.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Why combination products muddy the picture

Many of the most impressive berberine lipid trials did not test berberine. A food supplement combining red yeast rice, berberine, CoQ10 and hydroxytyrosol lowered LDL by 39 mg/dL in 4 weeks (PMID 28579756), but red yeast rice contains monacolin K, which is chemically lovastatin; the result belongs to a statin. Berberine paired with silymarin to improve absorption held lipids steady for 6 months in 137 statin-intolerant patients while the placebo group’s LDL rose 19.6 mg/dL (PMID 25577665), and a meta-analysis found the silymarin combination outperformed berberine alone (PMID 31441678). Those are real results for those products, not for a plain berberine capsule.

What we do not know

No trial has measured cardiovascular events or mortality. No trial has run longer than 52 weeks. The HDL sex difference has no explanation. And berberine’s oral bioavailability is very low, which raises the question of why it works at all; the leading hypothesis is action in the gut and on gut bacteria rather than in the bloodstream, which the PREMOTE lipid substudy supported when berberine plus Bifidobacterium breve outperformed either alone on postprandial lipids (PMID 34923903).

Doses used in studies

These are doses reported by the named sources, not recommendations.

• Trials pooled in PMID 36941490 commonly used 500 mg twice daily for 4 to 24 weeks.
• The Hong Kong men’s trial (PMID 34444711) used 500 mg twice daily for 12 weeks.
• The mild hyperlipidemia washout trial (PMID 27491226) used 300 mg three times daily for 3 months.

What this means for you

Berberine’s lipid effect is real, modest, short-term and untested on outcomes. Anyone comparing it with a statin is comparing a surrogate marker with a mortality trial. The full berberine evidence review grades all 11 claims; the side effects page covers the interaction with anticoagulants and cyclosporine.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.

Keep Reading on Healthcare Discovery

• Every Baby a Genome: How Newborn Sequencing Is Reinventing Precision Medicine
• AI Is Making Body Scans Cheaper. Medicine Still Has to Decide What They’re For.
• Curcumin for Joint Pain: What 15 Trials Show (2026 Evidence Grade)